Clinical trial NCT02450552: Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Official title: A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Amyotrophic Lateral Sclerosis
Keywords: Amyotrophic Lateral Sclerosis
ALS
Lou Gehrig
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: ALS Association
name: GlaxoSmithKline
name: Harvard University
name: Massachusetts General Hospital
First posted: 2015-05-21
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.

Detailed description: One of the major disease features of ALS is the progressive death of motor neurons. Human, rodent and stem cell-based model studies support the hypothesis that neuronal hyperexcitability may contribute to neurodegeneration in both sporadic and familial ALS. The investigators are doing this research study to find out whether retigabine will reduce motor neuron excitability in people with ALS. the investigators will also determine whether the drug is tolerable and safe for patients with ALS.

The proposed study will determine how the potassium channel opener ezogabine (retigabine) affects neurophysiological measures of upper and lower motor neuron excitability in ALS patients as assessed by transcranial magnetic stimulation (TMS) and threshold tracking nerve conduction studies (TTNCS), respectively. The study will include the recruitment of approximately 60 unmatched healthy control subjects for analysis of variability of the neurophysiological tests prior to recruitment of ALS subjects. There will also be 12 matched healthy control subjects, recruited at the same time as ALS subjects.

Eligibility criteria: ALS Subject Inclusion Criteria:

* Male or female, aged 18 to 80.
* Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.
* Slow vital capacity (SVC) measure ≥ 50% of predicted for gender, height and age at the Screening Visit,OR in the opinion of the SI, ability to perform and safely complete all study visit procedures.
* Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days prior to the Screening Visit and continue on the stable dose throughout the course of the study (riluzole-naïve subjects are permitted in the study).
* Subjects must be able to swallow oral medication at the Screening Visit and expected to be able to swallow tablets throughout the course of the study.
* Capable of providing informed consent and following trial procedures.
* Geographically accessible to the site.
* Women must not be able to become pregnant (e.g., post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal contraception, for example patch or contraceptive ring), intrauterine device (IUD) in place for ≥ 3 months, barrier method in conjunction with spermicide, or another adequate method.
* Use of medications known to affect the neurophysiology measures in the study must be scheduled, not as needed (pro re nata, PRN). A subject must have been on a fixed dose for 30 days prior to the Screening Visit, and there must be no reason to believe that a subsequent change would be necessary during the course of the study. These medications include: benzodiazepines, muscle relaxants, tricyclic antidepressants, selective serotonin reuptake inhibitors, non-selective serotonin reuptake inhibitors, hypnotics (including anti-histamines) and anti-cholinergics.
* TMS shows sufficient MEP amplitude and/or NCS studies show sufficient CMAP amplitude.

ALS Subject Exclusion Criteria:

* Medical condition, laboratory finding, or physical exam finding that precludes participation.
* Serum AST and ALT value \>2.0 times the upper normal limit
* Clinically significant conduction abnormalities on electrocardiogram or a known history of cardiac arrhythmia, myocardial infarction within the past 24 months, or congestive heart failure.
* Estimated glomerular filtration rate \< 50 mL/min at Screening Visit.
* Concomitant digoxin treatment.
* Known allergic reactions to components of the study product(s).
* Exposure to any other agent currently under investigation for the treatment of patients with ALS (off-label use or investigational) within 30 days of the Screening Visit including ezogabine, exposure to cell replacement therapy within six months of the Screening Visit or any prior intraparenchymal cell replacement injection within the spinal cord or brain at anytime in the past.
* Presence of tracheostomy at the Screening Visit.
* History of clinically significant urinary retention, , or current use of medications to treat urinary retention.
* History of drug and or alcohol abuse within 12 months of the Screening Visit.
* The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to SI judgment.
* Clinically significant history of unstable or severe cardiac, oncologic, hepatic, or renal disease, or other uncontrolled medical condition.
* Presence of feeding tube.
* Current use of antipsychotic, antiepileptic (except benzodiazepines, gabapentin, pregabalin) or class 1 (e.g. flecainide) or class 3 (e.g. amiodarone) antiarrhythmic medications. Quinidine or a quinidine-containing drug is allowed if the quinidine dose is not greater than 20 mg/day (for a full list of medications, please reference the study MOP).
* Inability to perform either TMS or NCS studies due to insufficient MEP or CMAP amplitude.
* Pregnant women or women currently breastfeeding.
* Contraindication to TMS studies including ferromagnetic metal in the head or neck (potentially found in aneurysm clips, implanted medication pumps, implanted brain stimulators, pacemakers, cochlear implants), or history of epilepsy. Dental fillings are permitted.
* Anything else that, in the opinion of the SI, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study.

Healthy Control Subject Inclusion Criteria:

* Male or female, aged 18 to 80.
* Absence of a known neurological disorder.
* Capable of providing informed consent and following trial procedures.
* Geographically accessible to the site.
* Age (+/- 10 years and site-matched to a ALS participant within 6 months of their Baseline visit).\[Matched controls only\]
* TMS shows sufficient MEP amplitude and/or NCS studies show sufficient CMAP amplitude (amplitudes defined in MOP).
* Use of medications known to affect the neurophysiology measures in the study must be scheduled, not as needed (pro re nata, PRN). A subject must have been on a fixed dose for 30 days prior to the Screening Visit, and there must be no reason to believe that a subsequent change would be necessary during the course of the study. These medications include: benzodiazepines, muscle relaxants, tricyclic antidepressants, selective serotonin reuptake inhibitors, non-selective serotonin reuptake inhibitors, hypnotics (including anti-histamines) and anti-cholinergics.

Healthy Control Subject Exclusion Criteria:

* History of ALS or other neurodegenerative disease.
* Presence of positive family history of ALS.
* Current use of an antipsychotic or antiarrhythmic medication
* Definitely or possibly pregnant.
* Contraindication to TMS studies including ferromagnetic metal in the head or neck ( potentially found in aneurysm clips, implanted medication pumps, implanted brain stimulators, pacemakers, cochlear implants), or history of epilepsy. Dental fillings are permitted.
* Anything that, in the opinion of the SI, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study.

Primary outcomes:
measure: Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS)
timeFrame: Screening, Baseline, Week 6, Week 8
Secondary outcomes:
measure: Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance)
timeFrame: Screening, Baseline, Week 6, Week 8
measure: Change in MEP Amplitude
timeFrame: Screening, Baseline, Week 6, Week 8
measure: Change in Duration of Cortical Silent Period
timeFrame: Screening, Baseline, Week 6, Week 8
measure: Change in Intracortical Facilitation
timeFrame: Screening, Baseline, Week 6, Week 8
measure: Change in Electrotonus
timeFrame: Screening, Baseline, Week 6, Week 8
measure: Change in Strength Duration Time Constant
timeFrame: Screening, Baseline, Week 6, Week 8
measure: Change in Recovery Cycle
timeFrame: Screening, Baseline, Week 6, Week 8
measure: Muscle Cramping Frequency
timeFrame: Week 1 through Week 10
measure: Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis
timeFrame: Screening, Baseline, Week 4, Week 6, Week 8, Week 12
measure: Proportion of Days With Fasciculations
timeFrame: Week 1 through Week 10
measure: Number of Participants Who Tolerate Study Drug
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Barrow Neuological Institute
state: Arizona
city: Los Angeles
country: United States
facility: Cedars-Sinai
state: California
city: Orange
country: United States
facility: UC Irvine Medical Center
state: California
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
city: Augusta
country: United States
facility: Augusta University (Georgia Regents Medical Center)
state: Georgia
city: Baltimore
country: United States
facility: Johns Hopkins Hospital
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: New York
country: United States
facility: Hospital for Special Surgery
state: New York
city: Durham
country: United States
facility: Duke University Hospital
state: North Carolina
city: Hershey
country: United States
facility: Penn State College of Medicine Milton S. Hershey Medical Center
state: Pennsylvania
Study officials:
affiliation: Massachusetts General Hospital
name: Brian Wainger, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maragakis NJ, Bedlack R, Goyal NA, Rutkove SB, Lange DJ, Rivner MH, Goutman SA, Ladha SS, Mauricio EA, Baloh RH, Simmons Z, Pothier L, Kassis SB, La T, Hall M, Evora A, Klements D, Hurtado A, Pereira JD, Koh J, Celnik PA, Chaudhry V, Gable K, Juel VC, Phielipp N, Marei A, Rosenquist P, Meehan S, Oskarsson B, Lewis RA, Kaur D, Kiskinis E, Woolf CJ, Eggan K, Weiss MD, Berry JD, David WS, Davila-Perez P, Camprodon JA, Pascual-Leone A, Kiernan MC, Shefner JM, Atassi N, Cudkowicz ME. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021 Feb 1;78(2):186-196. doi: 10.1001/jamaneurol.2020.4300.